FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals, Inc.’s (NASDAQ: REGN) Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other ...
Barchart on MSN

Regeneron’s Q3 2025 Earnings: What to Expect

Regeneron is expected to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit ...

Forecasting The Future: 9 Analyst Projections For Regeneron Pharmaceuticals

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $771.22, along ...
Fintel on MSN

Canaccord Genuity Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation

Fintel reports that on October 14, 2025, Canaccord Genuity maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) ...

You May Be Missing The Value In Regeneron Pharmaceuticals Stock

Here’s why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading ...
Nasdaq

November 7th Options Now Available For Regeneron Pharmaceuticals (REGN)

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Fintel on MSN

Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation

Fintel reports that on October 10, 2025, Morgan Stanley maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with ...